Inovio Pharmaceuticals (INO) jumped 19% on Jul 11, after it announced that its lead DNA medicine candidate, INO-3107, has received the Innovation Passport designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP). This designation was granted by the ILAP Steering Group for the treatment of recurrent respiratory papillomatosis (RRP).RRP is a rare degenerative disease that causes small growths (papillomas) in the respiratory tract. Generally, non-cancerous papillomas can cause seve ...